Secondary Logo

Journal Logo

PROTOCOL ALERT

doi: 10.1097/01.COT.0000293399.95112.87
Department: PROTOCOL ALERT
Free

The following is a partial list of new clinical trials recently added to the NCI's Physician Data Query (PDQ) database, accessible online at www.cancer.gov (Click on “Clinical Trials”).

Back to Top | Article Outline

Prostate Cancer

RO1-CA118003-01, NCT00330057, RO1-CA118003-01

Detection of Prostate Cancer With Contrast-Enhanced Ultrasound After Treatment With Dutasteride

Age: 18 to 80

Sponsor: Other

STUDY LEAD ORGANIZATION

Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Kelly Coggins; Ph: 215-955-4202; Email: kelly.coggins@jefferson.edu

RTOG-0415, NCT00331773

Phase III Randomized Study of Hypofractionated Versus Conventionally Fractionated Three-Dimensional Conformal or Intensity-Modulated Radiotherapy in Patients With Favorable-Risk Stage II Prostate Cancer

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

Radiation Therapy Oncology Group

W. Robert Lee, MD, Protocol chair; Ph: 336-713-6505, 800-446-2255

RTOG-0518, NCT00329797, 0518

Phase III Randomized Study of Zoledronate in Preventing Osteoporosis and Associated Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiotherapy and Luteinizing Hormone-Releasing Hormone Agonist Therapy

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

Radiation Therapy Oncology Group

Colleen Lawton, MD, Protocol chair; Ph: 414-805-4472; Email: colleen@mcw.edu

Matthew Smith, MD, Protocol co-chair; Ph: 617-724-5257, 877-726-5130

Margaret Chamberlain-Wilmoth, PhD, MSS, RN, Protocol co-chair; Ph: 704-687-4664; Email: mcwilmot@uncc.edu

FE200486 CS21, NCT00295750

Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens

Age: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

Ferring Pharmaceuticals, Inc.

Walter Pittman, MD; Ph: 205-930-0920

Kevin Tomera, MD; Ph: 907-276-1455

20050103, NCT00321620

Double-Blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Age: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

Amgen, Incorporated

Amgen Call Center; Ph: 866-572-6436

2005242-01H, NCT00326638, OTT 05-02

3D-Conformal Radiation Vs Helical Tomotherapy in Prostate Cancer

Age: 18 and over

Sponsor: Other

STUDY LEAD ORGANIZATION

Ottawa Health Research Institute

Scott Grimes; Ph: 613-737-7700, ext. 70523; Email: sgrimes@ohri.ca

Lorraine Millar; Ph: 613-737-7700, ext. 70306; Email: lmillar@ohri.ca

FRX106365, NCT00312013

Effects of Nadroparin In Patients with Lung, Pancreas, or Prostate Cancer

Age: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

GlaxoSmithKline

GSK Clinical Trials Call Center; Ph: 877-379-3718

Back to Top | Article Outline

Renal Cell Carcinoma

CECOG RCC 1.3.001, NCT00311467

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Age: 19 to 75

Sponsor: Other

STUDY LEAD ORGANIZATION

Central European Cooperative Oncology Group

Manuela Schmidinger, Prof., Principal Investigator; Ph: 43-1-40-400, ext. 4429; Email: manuela.schmidinger@meduniwien.ac.at

ECOG-E2805, NCT00326898, CALGB-E2805, CAN-NCIC-E2805, SWOG-E2805

Phase III Randomized Study of Adjuvant Sunitinib Malate Versus Sorafenib in Patients With Resected Renal Cell Carcinoma

Age: 18 and over

Sponsor: NCI

STUDY LEAD ORGANIZATION

Eastern Cooperative Oncology Group

Naomi Balzer-Haas, MD, Protocol chair; Ph: 215-728-2974, 888-369-2427

Cancer and Leukemia Group B

Christopher Kane, MD, Protocol chair; Ph: 415-353-7171, 800-888-8664

Southwest Oncology Group

Christopher Wood, MD, Protocol chair; Ph: 713-792-3250, 800-392-1611

NCIC-Clinical Trials Group

Michael Jewett, MD, Protocol chair; Ph: 416-946-2909; Email: m.jewett@utoronto.ca

Back to Top | Article Outline

Retinoblastoma

COG-ARET0322

Phase III Study of Adjuvant Vincristine, Carboplatin, and Etoposide or Observation Only in Patients With Newly Diagnosed Unilateral Retinoblastoma With or Without Histopathologic High-Risk Features After Enucleation

Age: 6 and under

Sponsor: NCI

STUDY LEAD ORGANIZATION

Children's Oncology Group

Murali Chintagumpala, MD, Protocol chair; Ph: 832-822-4266

Joan O'Brien, MD, Protocol co-chair; Ph: 415-502-0527; Email: aleja@itsa.ucsf.edu

Back to Top | Article Outline

Skin Cancer

MSLT-II, NCT00297895, NIH P01, CA029605

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Age: 18 to 75

Sponsor: Other

STUDY LEAD ORGANIZATION

John Wayne Cancer Institute at Saint John's Health Center

National Cancer Institute

Douglas E. Maier; Ph: 310-582-7427; Email: MaierD@jwci.org

CA184-024, NCT00324155

Phase III Study in Patients With Untreated Unresectable Stage III or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) Vs. Dacarbazine With Placebo

Age: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

Bristol-Myers Squibb Company, New York

Medarex, Inc.

BMS Call Center; Ph: 866-892-1BMS, ext. 364

BMS Call Center Outside the US & Canada; Ph: 941-906-4711, ext. 364

Back to Top | Article Outline

Miscellaneous/Other

CR003460, NCT00264095

A Study of the Management of Blood Loss in Patients Undergoing Surgical Removal of Tumors

Age: 18 and over

Sponsor: Pharmaceutical/Industry

STUDY LEAD ORGANIZATION

Janssen-Cilag B.V., Netherlands

Study Director; Email: info1@veritasmedicine.com

ELLA, NCT00280709

Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction

Age: 20 and over

Sponsor: Other

STUDY LEAD ORGANIZATION

University Hospital of Linkoping

Eric P. Kullman, MD, Study Chair; Ph: 46-13-222000, ext. 3545; Email: eric.kullman@lio.se

Per Sandstrom, MD; Ph: 46-13-222000, ext. 3556; Email: per.sandstrom@lio.se

© 2006 Lippincott Williams & Wilkins, Inc.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!